 |
|
 |
 |

Home > Company Index > Drugs > Drug Delivery > Access Pharmaceuticals, Inc.
 |
Access Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
Access Pharmaceuticals looks for ways to send drugs directly and effectively to the parts of the body that need treatment. The company develops drug-delivery systems for application in cancer treatment, dermatology, and oral diseases. Aphthasol, its only marketed product, is a canker sore treatment developed with and sold in the US by Block Drug; the drug is sold through other licensing agreements in Europe, the Near East, and Canada. Products in development include a polymer platinate to be used as a chemotherapy drug that will more effectively target tumors; ResiDerm, a topical zinc delivery system (already licensed to Strakan); and a treatment for mucositis called OraRinse.
COMPETITION |
 |
ALZA Corporation (dossier)
Medicis Pharmaceutical Corporation (MRX)
Pharmacia Corporation (PHA)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: 0.0%
Employees: 16
Revenue per employee: $6,250.00
KEY PEOPLE |
 |
Kerry P. Gray
CEO
Stephen B. Thompson
CFO
CONTACT INFO |
 |
2600 N. Stemmons Fwy., Ste. 176
Dallas, TX 75207
US
Phone: 214-905-5100
Fax: 214-905-5101
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |